



5 March 2020

ASX ANNOUNCEMENT

Medical Developments International announces leadership change

Medical Developments International Limited (ASX: MVP) today announced the resignation of its Chief Executive Officer, Mr. John Sharman. Mr. Sharman who has been with the company for almost 10 years, has chosen to pursue other business interests but will remain in the position for at least three months to assist with an orderly transfer.

Chairman of MVP, Mr. David Williams said: “on behalf of our Board, our staff and our shareholders, I would like to thank John for his outstanding leadership and significant contribution to the company over the last 10 years. During this time MVP has undergone a significant transformation, expanded geographically and enjoyed extraordinary commercial success that has shaped the company into a global pharmaceutical business. John has been a fantastic leader of our business, we congratulate him on his achievements. While we are sad to see John leave, this is a good opportunity to take the company to another level with a new leader.”

Chief Executive Officer of MVP, Mr. John Sharman, said: “I’m very grateful for the opportunity given to me by the stakeholders of MVP and would like to personally thank the Chairman, Mr. David Williams for his support. I am very proud of our achievements and am confident of MVP’s future worldwide success.”

David Williams said: “The Board will work closely with John and the MVP Leadership Team to manage the transition over the next few months. At the same time, we have started the search for a new outstanding candidate and leader that can spearhead our growth in the US and the EU, and bring our flow technology and related products to market.”

Authorised for release by MVP Chairman, David Williams.

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
+61 (0) 414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
+61 (3) 9547 1888



About Pentrox®

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox is now approved for sale in more than 40 countries and has been used safely and effectively for more than 40 years in Australia with more than 7.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast-acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

For personal use only